Publications

Publications

Real-time visualization and quantitation of vascular permeability in vivo: implications for drug delivery.

By:
Contributors: Andries Zijlstra Research Group, John D. Lewis Research Group, Desmond Pink, PhD
PLoS One. 2012;7(3):e33760. doi: 10.1371/journal.pone.0033760. Epub 2012 Mar 29.

Abstract

The leaky, heterogeneous vasculature of human tumors prevents the even distribution of systemic drugs within cancer tissues. However, techniques for studying vascular delivery systems in vivo often require complex mammalian models and time-consuming, surgical protocols. The developing chicken embryo is a well-established model for human cancer that is easily accessible for tumor imaging. To assess this model for the in vivo analysis of tumor permeability, human tumors were grown on the chorioallantoic membrane (CAM), a thin vascular membrane which overlays the growing chick embryo. The real-time movement of small fluorescent dextrans through the tumor vasculature and surrounding tissues were used to measure vascular leak within tumor xenografts. Dextran extravasation within tumor sites was selectively enhanced an interleukin-2 (IL-2) peptide fragment or vascular endothelial growth factor (VEGF). VEGF treatment increased vascular leak in the tumor core relative to surrounding normal tissue and increased doxorubicin uptake in human tumor xenografts. This new system easily visualizes vascular permeability changes in vivo and suggests that vascular permeability may be manipulated to improve chemotherapeutic targeting to tumors.

PubMed

Download PDF

APCaRI Registry and Biorepository enrolls 1500th participant – 30% of our goal

We are pleased to announce that the Alberta Prostate Cancer Registry and Biorepository reached 30% of its accrual goal by enrolling participant 1,500! To date more than 100,000 biosamples are stored in the Canadian Research Biorepository along with comprehensive clinical data – all available for cutting edge research.

This was possible thanks to our wonderful team of clinical research personnel, clinicians and partners who have been working collaboratively to reach our goals!

If you are interested in accessing biospecimens or clinical information, let us know at catalina.vasquez@ualberta.ca

Samples available from participants with prostate cancer and age-matched men with negative biopsy
  • Serum (400uL/vial)
  • Plasma (400uL/vial)
  • Buffy Coat (~300uL/vial)
  • Red Blood Cells (400uL/vial)
  • Urine (400uL/vial)
  • Semen (~400uL/vial)
Clinical Information available
  • Demographic information and co-morbidities
  • Family history of prostate cancer
  • Pathology and diagnosis details
  • Clinical and pathological staging
  • Treatment history
  • Outcomes
  • Biospecimen collection, sample availability and processing details
- Unknown